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Available online 26 April 2016trans-Epithelial delivery of medication across the vagina has proven successful for administration of small, lipo-
philic molecules such as sex steroids. However, little information is available regarding the vaginal delivery of
larger andmore polarmolecules that currently require parenteral administration because the vaginal epithelium
is perceived as a barrier to absorption of larger molecular weight (MW) molecules. Six healthy women
underwent administration of 18 or 36mg of leuprolide, a GnRH agonist and a largerMWpeptide, via a novel eth-
ylene vinyl acetate (EVA) ring transvaginal drug delivery system (TVDS). Serum levels rose within 8 h following
insertion: low dose at 310 pg/ml and high dose at 1220 pg/ml, i.e. levels typically following parenteral injections
of leuprolide. GnRHa biological activity was validated by secretion of gonadotropins and sex steroids. These re-
sults demonstrate that the non-keratinized vaginal epithelium permits a rapid absorption of a biologically active
peptide and that there is signiﬁcant potential for a novel TVDS to deliver peptides and possibly other macromol-
ecules therapeutically.
Signiﬁcance statement: Current routes of administration of medications can include oral, subcutaneous, intrave-
nous, intramuscular, transcutaneous, etc. Many of these approaches have limitations, including pain, poor toler-
ability, lack of adherence, and inadequate delivery. Peptides, in particular, cannot typically be given orally
because they are broken down in the intestinal tract before they are absorbed. While the skin is an attractive
way to deliver medications, its superb intrinsic barrier function often makes this route untenable at times. The
vaginal epithelium, in contrast, is not keratinized and can allow absorption of other molecules. In this study,
we demonstrate that a novel transvaginal drug delivery system (TVDS) is capable of delivering peptide therapeu-
tics to women in a non-parenteral fashion as demonstrated by both blood levels and biologic effects of its
delivery.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Transepithelial1. Introduction
Amajor therapeutic limitation of peptide and protein treatments has
been their requirement for intramuscular or parenteral administration.
Consequently, transepithelial delivery of medications has been an area
of substantial interest and research. Among the various cutaneousl Systems and the Swensrud
pital, 50 Staniford Street #240,
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rch.
. This is an open access article undersites for such medication delivery, the vagina is a potentially favorable
one not only for local but also for systemically acting drugs for several
reasons. These include: a) dense vasculature; b) lack of squamous kera-
tinization (a property shared only with the buccal mucosa, which is a
site incapable of supporting long term administration); c) direct access
to the systemic circulation; d) ability to circumvent the ‘hepatic ﬁrst
pass phenomenon’ inherent in oral administration; e) demonstrated
permeability to sex steroids [1]; f) potential for high drug absorption ca-
pacity in a sustained release fashion for weeks to months [1];
g) minimization of daily medication administration compliance issues;
and h) ease of use [2,3].
Despite these advantages, conventional wisdom is that vaginal ad-
ministration is limited by the molecular size of the therapeutic
agent(s) and their polarity due to size barriers inherent in skin epitheli-
um [4]. Additionally, physiological variations of the vaginal epithelium
throughout the menstrual cycle can affect both drug solubility and vag-
inal membrane penetration [1,5]. Despite these largely theoreticalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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solutions-landing/documents/elvax_molding_compounding_extrusion.pdf Accessed 8
October 2015.
8 Evatane® technical datasheets. Arkema. http://www.evatane.com/export/shared/.
content/media/downloads/products-documentations/altuglas-international/pof/
evatane/tds-evatane-18-150.pdf; http://www.evatane.com/export/shared/.content/
media/downloads/products-documentations/altuglas-international/pof/evatane/tds-
evatane-28-40.pdf; http://www.evatane.com/export/shared/.content/media/downloads/
products-documentations/altuglas-international/pof/evatane/tds-evatane-40-55.pdf
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9 Ron, Eyal S. and Tan, Hock, inventors; 2009 Oct. 22. Devices that include ethylene-
vinyl acetate copolymers and methods of making and using same. WO 2009129459 A1.
10 Evatane® technical datasheet. Arkema. http://www.evatane.com/export/sites/
evatane/.content/medias/downloads/tds/tds_33_45_PV.pdf DOI May 2012. Accessed 8
October 2015.
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small lipophilic molecules such as the naturally occurring sex steroids
estradiol and progesterone for hormone replacement therapy and syn-
thetic estrogens and progestins for contraception with substantial mar-
ket success in these two areas [6,7].
The normal functioning of the hypothalamic-pituitary-ovarian axis
critically depends upon the pulsatile secretion of Gonadotropin-
Releasing Hormone (GnRH) from the hypothalamus [8]. In contrast, con-
tinuous GnRH administration or long acting Gonadotropin-Releasing
Hormone agonists (GnRHa) pharmacologically desensitize pituitary go-
nadotropin secretion and silence all downstream gonadal function in
both sexes [9,10,11]. Thus, parenteral administration of a wide variety of
GnRH analogues have been used in women and men to induce a bio-
chemical castration over the past thirty-ﬁve years with therapeutic indi-
cations including the treatment of precocious puberty, endometriosis,
uterine ﬁbroids, and prostate cancer [12]. As restoration of normal repro-
ductive function in women promptly ensues following the discontinua-
tion of GnRHa administration, this biochemically-induced ‘medical
castration’ has provided a remarkably safe and reversible suppression of
reproductive function in all of these medical conditions over the past
three decades and now accounts for a several billion dollar annual phar-
maceutical market. However, all of these indications require periodic in-
jections since administration of a peptide is required.
In comparison with sex steroids, all GnRHa are peptides, larger and
more polar molecules. Systemic vaginal drug delivery of leuprolide,
the prototypical GnRHa, has been possible in experimental studies in
the rat as evidenced by their ability to stimulate luteinizing hormone
(LH) and follicle secreting hormone (FSH) levels following transvaginal
administration [13]. However, current vaginal ring technologies are in-
capable of continuously releasingmolecules over a few hundredmolec-
ular weight including peptides and proteins. To our knowledge,
transvaginal delivery of GnRHa, or for that matter any macromolecule,
has never been shown in higher animals or humans.
The present study was thus undertaken to design, develop, and test a
novel transvaginal delivery polymer system that could release larger mo-
lecular weight substances such as a peptide in the form of a prototypical
GnRHa, leuprolide (synthetic, man-made 9 amino acid sequence: p-Glu-
His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt) hormone that is similar to
the natural hormone, GnRH, that is produced in the brain. Importantly,
these tests were conducted in humans and measured both serum
GnRHa levels and physiologic responses of gonadotropin and sex steroid
responses. Leuprolide was selected as it is representative of the class of
GnRHa; is approximately 40× more potent than the natural sequence
GnRH; is commercially available; ismuch less polar that natural sequence
GnRH; and is capable of inducing pituitary gonadotropin desensitization
at far lower doses than the natural sequence GnRH.
All of the ﬁve commercially available transvaginal rings designed to
release small steroidal molecules (NuvaRing®, Femring®, Estring®,
Fertiring®, and Progering®) utilize a rate controlling membrane. How-
ever, these particular constructs enable the controlled release of only
low molecular weight molecules capable of passive diffusion through
the outer membrane. This particular design has the potential risk of
‘dumping,’ or rapid increases in serum levels of their contents, if a
break in the ring and/or the membrane occurs, as there is not a matrix
system underneath. Consequently, in order to release a larger peptide
such as leuprolide acetate via this route, a new intravaginal ring design
without a membrane, i.e. a homogenous cross-section ring, was devel-
oped. This vaginal ring system went through several critical design
steps in order to create formulation parameters that achieved desired
release kinetics for peptides. These included iterative optimization for
the appropriate size, mechanical properties, and stiffness that provided
desired release kinetics for a peptide alone or in combination with sex
steroids. This included a careful selection of the appropriate mixture of
medical grade ethylene-vinyl acetate (EVA) polymers and excipients
to control for stiffness/rigidity of the ring, minimization of the knit-
line formation, and to effectively control the release kinetics of thering. Finally, a scaled-up manufacturing approach to create rings that
could be approved for use in humans was developed.2. Methods
2.1. Ring design, construction, and loading
Selection of polymers for the ring was limited to medical grade EVA
(Evatane® by Arkema, France). This provides superior biocompatibility
over silicone-based polymers and also exhibits good mechanical prop-
erties. Evatane is a random copolymer of Ethylene and Vinyl Acetate
made by a high-pressure radical polymerization process.6 These special-
ty thermoplastic copolymers are inherently ﬂexible, resilient, tough,
and show excellent resistance to environmental stress cracking.7 Al-
though Evatane is available in various grades (varying ratio of ethylene
to vinyl acetate), they all possess similar general properties. The follow-
ing table (Table 1) demonstrates typical physical properties of three
Evatane polymers that were used8:
A scalable process of melt extrusion was developed to produce the
intravaginal rings under current good manufacturing practices (cGMP)
guidelines. (See Fig. 1).
EVA copolymer granules were cryogenically milled to reduce the
EVA bead size to a ﬁne powder.
Initial attempts to use Evatane showed that the some of the lots had
a high amount of vinyl acetate residues. In order to reduce the level of
monomeric vinyl acetate in EVA copolymer, the beads were washed
with water.9
150 g of Evatane 40–55 was weighed into a weighing pan. One liter
of de-ionized water was placed in a 2-L beaker and stirred using an
Arrow Engineering Mixer with a setting of 2.5. The polymer was
charged into the beaker while mixing. The copolymeric beads were
stirred in water for 20 min. After stirring, the material was ﬁltered
and collected. Evatane beads were washed nine times by repeating
the washing and ﬁltration cycle. Following the wash-ﬁlter cycle the
washed-ﬁltered beads were collected and further drained by passing
the copolymeric material through a 1700-μm sieve. Finally, Evatane,
along with the sieve, was placed in a vacuum oven for 48–72 h.10
The presence of residual (unreacted)monomeric vinyl acetate present
in EVA beads was determined using head-space gas chromatography
(HS-GC). The remaining vinyl acetate monomer of the raw and the
washed EVA beads were determined to be 1458 ppm and 0.9 ppm,
respectively.5
The intravaginal leuprolide acetate rings were prepared from the
washed polymer (EVA). 18 mg, 36 mg, or 54 mg leuprolide acetate
was dissolved or dispersed in approximately 10mL of ethanol in scintil-
lation vials, followed by the addition of 1400 mg of Evatane to the
ethanolic solution while mixing using a rotary shaker. The resulting
mixtures were solvent-casted in dry ice using ethanol as the solvent
(Pharmco; Cat. No. 111 USP 200 CSGL; Lot No. M8241). The solvent
Fig. 1. Flow diagram of scalable process of melt extrusion producing the intravaginal ring.
Table 1
Evatane grades that were used and their main typical properties1.
Speciﬁed properties⁎ Typical properties
Grades Vinyl acetate
content (%)
Melt index
(g/10mn)
Melting point
(°C)
Vicat point
(°C)
Ring & Ball
(°C)
Tensile strength at break
(MPa)
Elongation at
break (%)
Hardness
shore A
Density
(g/cm3)
18–150 17–19 135–175 88 47 102 10 300–500 85 0.94
28–40 27–29 35–45 70 b40 106 10 800–1000 73 0.95
40–55 38–41 48–62 54 b40 97 7 900–1100 50 0.96
Test method FTIR ASTM D1238 D.S.C. ASTM D1525 ASTM E28 ASTM D638 ASTM D2240 ASTM D1505
ISO standard 1133 11,357 306 NF EN1238 527 868 1183
Melt index done at 190 °C and under 2.16 kg.
(*) Properties routinely measured during the standard quality control procedure.
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were then ground into powders.11
The milled EVA polymers were combined with the initial blend or
granulation of leuprolide acetate (PolyPeptide Laboratories Inc.),
PEG4000 (Union Carbide Corp/Dow Chemical Co.), and Polysorbate 80
(Uniqema/Croda PLC) to produce leuprolide acetate/EVA granulation
that was fed to the extruder, after which the extrudate was pelletized
and rings were formed by injection molding. The resulting rings were
individually wrapped in moisture- and light- protective packaging to
protect the GnRHa peptide.
The EVA/drug powders were placed in an injection molding unit
(DSM, Geleen, Holland). The injector was heated to approximately
80 °C. The molten EVA/drug compositions were extruded into stainless
steel mold at 10 °C, creating a ringwith an outer diameter of 50mmand
a cross section of 4 mm.1211 Ron, Eyal S. et al., inventors; 2011 Nov. 17. Devices and methods for treating and/or
preventing diseases. United States patent US 20110280922 A1.
12 Ron, Eyal S. and Tan, Hock, inventors; 2009 Oct. 22. Devices that include ethylene-
vinyl acetate copolymers and methods of making and using same. WO 2009129459 A1.The formed intravaginal EVA rings were tested for their properties
(physical appearance, identiﬁcation, potency, related substances/impu-
rities, leuprolide acetate release rate, see Table 2) and supplied to the
clinic.
A typical process was conducted as follows:
A 750 g batch of leuprolide acetate extruded pellets, 2.4% w/w, was
manufactured using the components described in Table 3 below13:
2.1.1. Primary mixing
30 g of polyethylene glycol, NF was placed in the bowl of a GMX-Lab
Micro High Shear Mixing System with a 1 l bowl and 1 l blades. The
GMX-Lab Micro was closed with the chopper set to OFF. The polyethyl-
ene glycol, NFwas thenmixedwith a plow speedof 155 rpm for approx-
imately 30 s. 18 g of the leuprolide acetate was then added into the 1 l
bowl of theGMX-LabMicro. The remaining30 g of thepolyethylene gly-
col, NFwas used to rinse the liner from the leuprolide acetate into the 1 l
bowl of the GMX-Lab Micro. The GMX-Lab Micro was then closed with13 Ron, Eyal S., inventor; 2013 Jun. 20. Vaginal Drug Delivery Devices andManufacturing
Methods. WO/2013/090871.
Table 2
Release properties of the intravaginal EVA rings.
Attribute Acceptance criteria
Physical appearance Translucent whitish ring
Identiﬁcation EVA by FTIR, conformed to typical IR peaks
Leuprolide by RP-HPLC, conformed to the retention time
Assay 90.0–110.0% of label claims as free base
Content uniformity USP b905N (AV b 15)
Related substances/impurities Individual: NMT 1.0% Total: NMT 5.0%
Compression force 10 mm Report results
20 mm
30 mm
33 mm
Dissolution (pH 4) - Report results of cumulative release over 28 days (%)
- Report results of sampling and assay at: 1 h, 4 h, 1, 2, 3, 5, 7, 10, 14,18, 21, 25 and 28 days
Microbial limit test Aerobic plate count: b100 cfu/g - Absence of Pseudomonas aeruginosa
- Absence of Staphylococcus aureus
- Absence of Candida albicans
Yeast & mold plate count: b10 cfu/g
Further optimization of the ringmanufacturing process took placewhile clinical trials were being conducted. The goalwas to create a scalable process that will form intravaginal rings that
meet the performance criteria as it was set out above.
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from the syringe into the GMX-Lab Micro bowl while mixing with a
plow speed of 155 rpm. The combination was mixed for approximately
3 min.
2.1.2. Secondary mixing:
332.25 g of ethylene vinyl acetate copolymer, milled (Evatane EVA
18–150, milled) was then added into the bowl of a GMX-Lab Micro
High Shear Mixing System with a 4 l bowl and 4 l blades (1st Layer).
The polyethylene glycol, NF, leuprolide acetate, and Polysorbate 80, NF
mixturewas then collected from theGMX-LabMicro 1 l bowl and trans-
ferred to the 4 l bowl of theGMX-LabMicro (2nd Layer). 332.25 g of eth-
ylene vinyl acetate copolymer, milled (Evatane EVA 28–40, milled) was
then added into the 4 l bowl of the GMX-Lab Micro (3rd Layer). The
GMX-LabMicrowas closed and the combinationwasmixed for approx-
imately 5 min at 425 rpmwith the chopper set to ON, low speed range.
The blend was then transferred into a container double lined with poly
bagswith 2 desiccant, 4 unit silica gel between the inner and outer liner.
2.1.3. Hot melt extrusion procedure
A Leistritz ZSE 18 HP Extruder System with a 25:1 extruder barrel
was arranged with the following barrel conﬁguration: Open Barrel
(Feed); Closed Barrel; Closed Barrel; Open Barrel (Vent); Closed Barrel;
Final Melt Plate. The 25:1 length/diameter ratio twin screws were as-
sembled as shown in Fig. 2 and installed into the extruder. A 3.0mmsin-
gle bore round die and spacer was installed onto the ﬁnal melt plate.
Supply and return connections were made between a Tempered
Water Generator (TWG) and the extruder. In particular, tempered
water lines were connected to the extrusion barrel manifold, one set
of cooling water lines was connected to the feeding barrel, one set ofTable 3
Components of leuprolide acetate extruded pellets, 2.4% w/w.
Component % w/w of
extrudate
Theoretical amount for
750 g
Amount
dispensed
Evatane 28–40 44.3 332.25 332.25
Evatane 18–150 44.3 332.25 332.25
PEG 4000 8.0 60.0 60.0
Polysorbate 80, NF 1.0 7.5 ⁎7.575
Leuprolide Acetate 2.4 18.0 18.0
Total extrusion blend 100.0 750 750.075
⁎ The listed components were dispensed according to the mass listed in the far right
column. 7.575 g of Polysorbate 80, National Formulary (USP-NF) (NF) was dispensed into
a 60mL syringe. A1% excess of the Polysorbate 80, NF over the theoretical amount of 7.5 g
was dispensed to allow for residual losses in the syringe.cooling lines was connected to the gear box, and all supply and return
valves were placed in the open position.
The TWG and pumpwere turned on, the chilled water set point was
adjusted to 13.0 °C, and the tempered water set point was adjusted to
30.0 °C. A K-Tron KCL24T20 Feederw/ 12mmdiameter 20 pitch screws
was connected to, and positioned behind the extruder. The K-Tron was
bonded/grounded to the extruder and the impeller inside of the feeder
hopper was installed so as not to touch the wall of the hopper. The ex-
truder was turned on and the temperature set points for each heating
zone were set according to Table 4 below:
A 30-min wait time was observed to allow the extruder to reach
thermal equilibrium. The K-Tron feeding method was set to normal
and the K-Tron feeder hopper was ﬁlled with the blend from the
GMX-Lab Micro described above. The feed rate was set to 0.75 kg/h
and the K-Tron was run until the material began to ﬂow to prime the
feed screws. The K-Tron's auto calibration routine was then executed
and the K-Tron was aligned with the extruder feed opening. The K-
Tron feeder was set to Gravimetric Dosing mode and the feed rate set
point for the extruder was set at 100% for feeder 1 and 0.0% for feeder
2. A Dorner Cooling Conveyer was aligned with the extruder die with
cooling fan 1 OFF and fans 2, 3, and 4 ON.
The feed opening of a Scheer Bay BT-25 Pelletizer was aligned at the
end of the cooling conveyor. A container double lined with poly bags
with 2 desiccant, 4 unit silica gel between the inner and outer liner
was placed beneath the pelletizer discharge chute to collect the pellet-
ized material.
The screw drive was started at a rate of 10.0 rpm and the screws
were allowed to turn a few revolutions to ensure proper installation.
The screw speed was then increased to 50 rpm (+10 rpm) and feeder
1 was started at 100% of the feed rate total for an effective feed rate of
0.75 kg/h (+0.2) kg/h. The cooling conveyer was bypassed and the ex-
truder was run into a waste container for 5 min, or until the extrudate
was translucent with no dark spots. The conveyer and pelletizer speeds
were adjusted to draw the extrudate in such a way as to produce pellets
approximately 5 mm or smaller. The product funnel on the extruder
was monitored to ensure buildup of material did not occur. If excessive
build-up was observed, excess material was vacuumed from the prod-
uct funnel area. During the batch, the heated zone set points were ad-
justed within the ranges noted in Table 4 above to maintain the target
temperature.
The extrudate was visually examined to verify that the extrudate
was translucent with no dark spots. If extrudate appearance became
opaque or output decreased, the melt plate was heated to 80 °C to
90 °C using a torch. The K-Tron feeder hopper was reﬁlled as necessary
and set to the Gravimetric Dosingmode after each re-ﬁll. The pelletized
extrudate was added into an 8 quart V-Shell blender and blended for
Fig. 2. A schematic diagram of the barrel and the elements conﬁguration of the extrusion system.
Ron, Eyal S., inventor; 2015 Jan. 1. Vaginal Drug Delivery Devices and Manufacturing Methods. United States patent US 20150004213.
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container double lined with poly bags with 2 desiccant, 4 unit silica
gel between the inner and outer liners.Fig. 3. One of the two mold plates.3. Injection molding procedure
The pelletized and blended extrudate was then transferred to the
hopper of a Sesame Nano-Molder Injection Molding Machine conﬁg-
ured with the mold plates of Fig. 3, which deﬁned a mold cavity with
a 4 mm minor ring diameter and a 54 mm major ring diameter. A
ring-shaped drug delivery device was injection molded using a
2.0 mm circular nozzle, a molding pressure of 1550 bar, a speed setting
of 100 mm per second, a mold temperature of 55 °C, and a barrel tem-
perature of 85 °C. The ﬁnished drug delivery device was then allowed
to cool and removed from the mold.
To determine the ring's mechanical performance, a model was devel-
oped which mimics the intravaginal mechanical forces that a TVDS may
typically experience due to increased intra-abdominal pressure (e.g.
coughing, running, or defecating) [15]. This method measures the ring
compressibility (elastic modulus) by determining the mechanical force
required to reach a ﬁxed distance at four compression points: 10, 20, 30
and 33 mm. NuvaRing® was used as a standard comparator due to its
high level of patient acceptability [16]. A summary of the different formu-
lations, including the different EVAweights and excipients thatwere test-
ed for their mechanical properties is shown in Tables 5 and 6.
Higher molecular weight blends of EVA (e.g. Batch A) provided
higher ring rigidity similar to the rigidity of NuvaRing®. It was found
that a composition of EVA Copolymer with 28% vinyl acetate (VA) con-
tent, (Evatane® 28-40) blended with EVA Copolymer with 18% VA con-
tent (Evatane® 18-150) provided the optimum mechanical properties
balancing rigidity and ﬂexibility.
The ring had an acceptable compression force that supported easy
insertion by the woman, yet once in place allowed it to re-expand to
its original round shape and resist the mechanical stress inside the vag-
inal cavity, thus increasing the intravaginal retention of the rings. The
addition of vaginally-accepted excipients [14] allowed us to modify
the release kinetics iteratively while acting as plasticizers to reduce
themechanical stiffness of the neat polymers to an acceptable compres-
sion force.Table 4
Temperature Set Points for Extruder Heating Zones.
Zone Feeding zone 1 2 3 4 Melt plate
Set point (°C) N/A 80 80 80 80 Record actual
Set point range (°C) N/A ±10 ±10 ±10 ±10 N/A
On/off Off On On On On Off3.1. Subjects
This study was reviewed and approved by the Institutional Review
Board of the Partners Healthcare system and conducted at Brigham
and Women's Hospital. Written informed consent was obtained and
documented in accordance with the Declaration of Helsinki. Healthy
normal volunteers were recruited to participate in a three-day outpa-
tient study beginning between days 1–7 of their menstrual cycle
(i.e., the early follicular phase), duringwhich there is a nadir of their en-
dogenous sex steroid hormone levels. A negative urinary human gonad-
otropin test was obtained prior to study initiation to assure their non-
gravid state. Twenty-two female subjects aged 18–40 years were
screened for the study; ten screen-failed and the remainder were lost
to follow-up. Reasons for screen failure included laboratory abnormali-
ties, such asmildly elevated baseline LFTs and prolactin levels, increased
BMI, and irregular menstruation. Six subjects were lost to follow up be-
fore their baseline visit, and six subjects participated. The demographics
of the six participants are included in Table 7.3.2. Trial design
On the ﬁrst study day, four baseline blood samples of 5 mL were
drawn at 20-min intervals over an hour (Time = 0, +20, +40, +60)Table 5
Component formulations of rings.
Sample
name
Batch
A
Batch
B
Batch
C
Placebo (neat
EVA)
Placebo (with
excipients)
EVA 18–150 44.3% 44.3% 44.3% 50% 45.5%
EVA 28–40 44.3% 44.3% 50% 45.5%
EVA 28–25/25 44.3%
PEG 4000 8% 8% 8% 8%
Tween 80 1% 1% 1% 1%
Leuprolide 24 mg/g 24 mg/g 24 mg/g
Table 7
Subject demographics.
Subject Race BMI LMP Menstrual cycle (days) Date of insertion
1 White 19.8 5/22/2008 30 6/24/2008
2 White 22.8 6/16/2008 28–31 7/15/2008
Table 6
Formulation of an intravaginal ring containing leuprolide acetate.
Sample name 2010-024-09 2010-024-11 2010-024-16 2010-024-36 NF1
EVA 18-150 44.3% 44.3% 44.3% 44.3% 88.6%
EVA 28-40 44.3% 44.3% 44.3% 44.3% –
PEG 4000 8% 8% 8% 8% 8%
Tween 80 1% 1% 1% 1% 1%
Leuprolide 24 mg/g 24 mg/g 24 mg/g 24 mg/g 24 mg/g
Comments Pilot equipment 0.5 kg/h Pilot equipment 0.1 kg/h Pilot equipment 0.1 kg/h Pilot equipment 0.1 kg/h Bench top preparation
24 A.B. Kimball et al. / Journal of Controlled Release 233 (2016) 19–28and pooled to determine pretreatment levels of leuprolide, gonadotro-
pins, and sex steroids. The vaginal rings were then inserted on the
morning of Day 1. The ﬁrst cohort of three women received vaginal
rings containing 18 mg of leuprolide acetate, and the second cohort of
three subjects received 36 mg. Subsequent labs were drawn at noon
and 4–5 pm on Day 1, and at 8–9 am, noon, and 4–5 pm on the two fol-
lowing days. The rings were withdrawn on Day 3. Serum levels of
leuprolide, LH, FSH, estradiol, and progesterone were determined on
all samples.
3.3. Safety and tolerability
A visual examination of the vaginal epithelium was conducted at
baseline and daily thereafter and ﬁndings recorded in a standard man-
ner. A colposcopy was conducted at baseline before ring insertion and
on Day 3 after ring removal to ensure no changes (e.g. evidence of in-
ﬂammation) in the vaginal epithelium occurred.
3.4. Assay methodologies
All reproductive hormone levels were determined by the Reproduc-
tive Endocrine Unit Reference Core Assay Laboratory of the Massachu-
setts General Hospital, which is both a GLP-compliant and CLIA-
certiﬁed site. All serum samples were coded and blinded by the clinical
research teamprior to submission to the laboratory. The hormone levels
from the experimental subjects were compared to normative data from
120 normal ovulatory menstrual cycles in which daily levels of gonado-
tropins and sex steroids were determined [19].
Serum leuprolide levels were measured by a commercial enzyme-
linked immunosorbent assay (ELISA) method using a commercial kit
(Catalog # S-1144, Peninsula Laboratories, LLC). This immuno-assay is
widely used for pharmacokinetic research studies of leuprolide, but it
does not distinguish between intact leuprolide and its breakdown frag-
ments. Results therefore represent a combination of intact andmetabol-
ic products and thus serve as a composite index of the changes in
relative drug concentrations. All specimens from each participant's
study were tested in the same assay whose minimum detectable con-
centration was b50 pg/ml with a reportable range of 50–2000 pg/ml.
Seven of the total of 53 specimens from all study subjects contained
b50 pg/ml, i.e. the limit of assay sensitivity. These seven samples were
constituted of mostly baseline and early sampling determinations
from the low dose group.
4. Results
4.1. Controlling release kinetics
The in vitro release of leuprolide over time was determined in pH 4
buffer media. This is representative of the local pH of a normal healthy
vagina, and is also a pH that is typically employed to measure the
in vitro drug release characteristics from intra-vaginal rings. The pKa
of leuprolide acetate is reported as 9.6.14 Leuprolide acetate has three14 CDER Application Number 21–379 Clinical Pharmacology and BioPharmaceutics Re-
view(s): Eligard 22.5 mg (LA-2550). Atrix Laboratories, Inc. http://www.accessdata.fda.
gov/drugsatfda_docs/nda/2002/21-379_Eligard_biopharmr.pdf. Accessed 30 March 2016.ionizable sites: the imidazaloyl nitrogen of histadine (pKa = 6), the
phenolic hydroxyl of tyrosine (pKa = 10), and the guanidine nitrogen
of arginine (pKa = 13). The resultant pKa value is attributed to both
the tyrosinemoiety and the extremely basic guanidine nitrogen. In con-
sequence, leuprolide is predominantly ionized over the pH range that is
of physiological relevance, so these test conditions were considered to
be appropriate. Similarly, in vivo, we could also expect only minor dif-
ferences in vaginal absorption of the drug to occur within the known
pH variations that exist between different ethnicities and population
age groups and also in womenwith lowered vaginal lactobacillus levels
where the pH also increases towards neutrality.
We previously demonstrated that the drug particle size affects the
release kinetics from a homogenous matrix with larger particles in-
creasing the contact area between adjacent particles to create a less tor-
tuous path resulting in faster release kinetics [17,18]. Thus,
incorporating drugs with different drug particle sizes and loading
could be used to adjust the desired release kinetics. Batches B and C
had the same formulations (Table 5), but Batch C was processed at a
lower extruding rate (0.1 vs 0.5 kg/h). The extruding rate did not affect
themechanical properties of the formed rings. Similarly, adding various
excipients to the EVA mixture did not noticeably affect the mechanical
properties of the rings. However, Batch A was made with EVA that
had a lower melt ﬂow index (i.e. higher MW), and as a result the me-
chanical properties of Batch A in comparison to Batches B and C
(Table 5) displayed ca. 50% higher compression force of 400 g at
33 mm (Fig. 4).
To enable the release of larger molecular weight molecules such as
leuprolide acetate, which require low drug loading, excipients needed
to be added to allow continuous zero order kinetic drug release to be
achieved. This pattern of drug release was one of our goals in designing
this system. These excipients could be porosigens, i.e. excipients added
to the drug to create the physical contact between the different particles
that allow the drug to continue to be released from the matrix. As the
excipients diffuse out of the ring matrix, the porosigens create tortuous
paths for diffusion of the entrapped drugs should the drug particles be
too small and not in contact with each other. Alternatively, some excip-
ients can act as plasticizers that affect the diffusion of the drug through
the EVAmatrix for drugs that are soluble in this matrix, such as estradi-
ol. The effect of different plasticizing excipients (such as polysorbate or
polyethylene glycols) on the release kinetics is presented in Fig. 5.
Formulation 1 includes only estradiol with no excipients, while For-
mulation 2 has additional plasticizers that accelerate the release kinetics
by improving thediffusion of the estradiol through theEVA. Considering
all these variables, we investigated different formulations that would
allow us to create an intravaginal ring containing leuprolide acetate
(Table 6).3 White 23.7 8/4/2008 28 8/5/2008
4 White 28.9 7/5/2008 25–28 9/23/2008
5 White 23.4 8/29/2008 30 10/21/2008
6 Hispanic 22.8 10/15/2008 30 12/9/2008
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However, formulation NF1, with less vinyl acetate (without EVA 28–
40), provided prolonged release with slower drug release rates.
Ultimately, EVA rings were loaded with either 18 mg of leuprolide
acetate, which was anticipated to release ~50 μg/day, or 36 mg which
was estimated to release ~100 μg/day. These levels were calculated to
be sufﬁciently high to induce a relatively complete desensitization of pi-
tuitary gonadotropin secretion and consequent ovarian quiescence
given good vaginal absorption.Fig. 5. Effect of inclusion of plasticizing excipients on estradiol release.4.2. Human studies
Six women met the eligibility criteria that included: normal healthy
females aged 18–40, a BMI between 19 and 29, normal prolactin levels
and a negative pregnancy test at the time of enrollment. Their average
age was 26 years (range 18–40 years) and no leuprolide was detected
in their baseline bloods. There were nine patients screened who did
not meet exclusion criteria and the reasons were as follows: abnormal
laboratory results, Body Mass Indexes (BMIs) greater than allowed in
the study, and irregular menses. Following insertion of the GnRHa
rings, serum leuprolide concentrations rose in all six females to a
mean of 310 pg/ml in the low dose and 1220 pg/ml in the high dose
group that peaked onDay 1. Fig. 7 demonstrates these results graphical-
ly along with known published data on expected serum levels of
leuprolide parenteral depot injection.
Mean serum leuprolide levels rose from 100 pg/mL levels to a peaks
of 310 pg/ml in the 18 mg dose group and from 90 pg/mL to a peak of
1220 ng/ml in the 36 mg group within 8 h of vaginal ring insertion
and remained elevated compared to baseline over the full three day
course of study in the 36 mg group. By Day 3, mean leuprolide levels
remained detectable with a mean of 160 pg/ml in the 18 mg group
and 310 pg/ml in the 36 mg group.Fig. 4. Effect of polymer melt ﬂow inParallel increases of serum FSH (Fig. 8a), LH (Fig. 8b), and estradiol
(Fig. 8c) occurred, conﬁrming the biological activity of the leuprolide
detected by ELISA. Serum FSH levels peaked at 11.2 mIU/ml in the
18 mg group and 24.4 mIU/ml in the high dose group. Similarly,
LH levels peaked at 20.8 mIU/ml in the low dose group and at
46.2 mIU/ml in the high dose group relative to mean of the normative
early follicular phase values of anticipated for this stage of themenstrual
cycle (5.4 mIU/mL). These elevations of LH and FSH levels were rapid,
with the most dramatic increase observed 8 h post-ring insertion for
both gonadotropins. Compared to the daily normative data from 120
normal female early follicular phases indicating an average FSH
(7.3 mIU/mL), these FSH levels were also clearly elevated in the
study subjects. Although the sample size was small, all subjects index on ring compression force.
Fig. 6. Effect of extrusion rate on leuprolide release rate.
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er than one standard deviation outside of the maximal reference
value. Two of the three subjects in the low dose group also demon-
strated peak LH and FSH levels greater than one standard deviation
outside of this reference range.
Consistent with the biologic activity representative of the leuprolide
entering the circulation, elevated estradiol and progesterone levels oc-
curred, lagging behind the gonadotropin secretion in a typical fashion.
While FSH and LH secretion peaked on Day 1, subsequent increases in
estradiol were observed on Day 2 with the time to peak estradiol
concentrations varying between subjects. The low dose group peaked
at 122 pg/ml (56–239 pg/ml), whereas the high dose peaked at
138 pg/ml (88-208 pg/mL) relative to the normative early follicular
phase values anticipated of 61 pg/ml. One subject in the low dose
group had a dramatic increase in her serum progesterone, suggesting
some residual functioning of her corpus luteum from the previous
cycle that is often seen during GnRHa administration during the early
follicular phase of the menstrual cycle. However, serum progesterone
levels in all the remaining subjects demonstrated only mild increases
in progesterone secretion in both low and high dose GnRHa groups.
One subject in the high dose GnRHa group had peak levels of serum
leuprolide of 2000 pg/mL. This same subject also demonstrated the
most dramatic increases in peak FSH (37 mIU/ml) and peak LHFig. 7. Mean serum leuprolide levels as measured by GnRH ELISA assay in low dose
(18 mg) and high dose (36 mg) vaginal rings compared to published data on parenteral
depot injection.
Fig. 8. a: Mean serum FSH concentration post-EVA ring insertion in low dose (18mg) and
high dose (36 mg) cohorts compared to normative data of early follicular phase b: Mean
serum LH concentration post-EVA ring insertion compared to normative data of early
follicular phase c: Mean serum estradiol concentration post-EVA ring insertion
compared to normative data of early follicular phase.(60.6 mIU/ml). By three days post-GnRHa administration, elevation
in her serum concentrations of leuprolide (430 pg/ml), FSH
(8.3 mIU/ml), and LH (10.2 mIU/ml) persisted. This elevated serum
LH remained N1SD above the maximal reference value at three
days post-insertion.
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All study subjects tolerated the rings well and without any evidence
of vaginal irritation by visual inspection or colposcopy. Vaginal ring dis-
placement occurred in three of the six subjects; in subjects 2 and 3, the
ring dislodged overnight between Day 1 and Day 2 associated with
Valsalva maneuvers but was easily replaced by the subjects themselves
and validated as to their location by the primary investigator on Day 2.
The rings that were tested in this study were designed primarily for
their drug elution and delivery properties. They were not optimized
for their ‘ﬁt and feel’ and patient comfort. As a result the rings were, at
times, ejected from the vaginawhen a few individuals exhibited any in-
ternal pressure, through defecating, coughing etc. Interestingly, these
temporary dislocations did not appear to affect absorption of leuprolide
signiﬁcantly in subject 2 but may have in subject 3.
5. Discussion
This study demonstrates that effective, non-parenteral absorption of
a polar peptide of considerably larger size than sex steroids could be
achieved via delivery from a novel vaginal ring delivery system with
resulting therapeutic serum levels of GnRHa. The agonist biological ac-
tivity of the circulating GnRHa was conﬁrmed by subsequent elevations
of serum LH and FSH and ovarian sex steroid secretion. To provide some
context for these results, a single intramuscular injection of the three
month Leuprolide® Depot injection containing 11.25 mg produces a
meanplasma leuprolide concentration 36.3 ng/mL4 hpost-intramuscu-
lar injection. After reaching steady state byweeks 3–12, however, mean
circulating leuprolide concentrations subsequently plateau to levels of
230 = /−90 pg/ml (SS) at 12 weeks, i.e. levels sufﬁcient to maintain
the desired therapeutic suppression of the pituitary-gonadal axis for
3 months with these levels. Although the present study was limited to
a 56 h period per FDA requirements, the resulting serum levels of
leuprolide achieved in both the low and high dose groups achieved
this target range within hours of vaginal application of our ring.
Vaginal rings are well established to deliver relatively physiological
levels of natural estradiol and progesterone systemically for hormone
replacement treatment inmenopausalwomen, aswell as pharmacolog-
ic levels of synthetic steroids for contraception in reproductively active
women, to circumvent the known hepatic ﬁrst pass phenomenon of
synthetic sex steroids that occurswhen administered orally. The current
studies now demonstrate the potential feasibility of developing a vagi-
nal ring drug delivery system that could extend the therapeuticwindow
of transvaginal delivery to combine the established systemic delivery of
sex steroids with that of a larger peptide such as a GnRHa. Such a com-
bined ‘GnRHa+ sex steroid’ TVDS ring could potentially be used to ad-
minister GnRHa to induce a complete quiescence of the pituitary-
ovarian axis that would completely block ovarian folliculogenesis and
steroidogenesis but also permit coincidental administration of physio-
logic levels of natural estradiol and progesterone (i.e. ‘add back’ regi-
mens). The advantage of this combination would be to maintain
physiologic levels of sex steroid to support responsive target organs of
bone, vaginal epithelium, and abolish the CNS effects of GnRHa-
induced biochemical castration with hot ﬂashes.
Such combination rings containing GnRHa + natural sex steroids
would be useful in two clinical settings. Inwomenwith polycystic ovar-
ian disease (PCOD), one therapeutic goal is to suppress ovarian andro-
gen secretion that drives their hirsutism and potentially contributes to
their insulin resistance while avoiding the castrational side effects of
GnRHa administration alone [20]. In addition, it would also be possible
to add insulin-sensitizing agents to these rings to treat their insulin
resistance in theory. Similarly, GnRHa's ability to completely suppress
gonadotropins and hence ovulation to provide contraception has tradi-
tionally been limited by the side effect of leaving women with hot
ﬂashes, decreased bone density, and vaginal atrophy. Combining phys-
iologic ‘add-back’ of natural sex steroids with GnRHa administrationwould thus open the possibility of using such a combined vaginal ring
in a contraceptive mode.
In addition, a current standard therapy for women with endometri-
osis is to combine intramuscular leuprolide injections with oral noreth-
indrone acetate to control the castrational symptoms that typically
accompany isolated GnRHa therapy. However, oral norethindrone ace-
tate is subject to both ﬁrst hepatic ﬁrst pass metabolism and the vaga-
ries of patient compliance. A transvaginal drug delivery system that
could co-administer controlled release of a GnRHa and simultaneously
add back sex steroid hormones would thus open a considerably wider
range ofmore convenientmethods of drug delivery in several important
clinical settings. It could also support the co-administration of other
medications such as anti-HIV treatments that have been shown to re-
duce infectivity when administered transvaginally but which often be-
come limited by compliance [21].
Several limitations of this study exist. The number of subjects and
duration relate to FDA imposed IND restrictions. Also the population
size was too small to detect statistically signiﬁcant differences between
the low andhigh dose groups; however, the trends are consistentwith a
dose-response relationship between ring leuprolide concentrations in
addition to their physiologic effects. The low dose ring was inserted im-
mediately at the end of subject 1′s menses as opposed to subjects 2 and
3 inwhom the ringwas inserted at the beginning of theirmenses. Inser-
tion of the ring at the end of their menses, i.e. in themiddle of the follic-
ular phase, likely explains the more exuberant rise in estradiol seen in
subject 1.
Future research should examine longer time courses in larger num-
bers of subjects to induce complete reproductive quiescence investigate
and titrating GnRHa dosing to achieve target serum concentrations.
Longer-term studieswill also help to determine the stability of hormone
release which, according to our in vitro studies, follow near zero order
kinetics and are stable for weeks. The results of this study suggest that
the use of a vaginal ring for controlled and constant delivery of a large
peptide, such as GnRH agonists, is not only feasible but represents a po-
tentially novel therapeutic platform that will enable several potentially
interesting treatments or combinations of treatments in a variety of
clinical settings. Currently, there are other FDA-approved combinations
of a contraceptive vaginal ring containing two synthetic steroids,
etonogestrel and ethinyl estradiol (NuvaRing®). Although delivery of
proteins has been previously demonstrated from vaginal rings, such
studies have employed IVR's of more complex designs which comprise
a ring body into which a drug-loaded inserts is placed [22]. Our study
utilizes a simplematrix design IVRwithout incorporating a rate control-
ling membrane. The biological and therapeutic implications of this
study extend beyond the clinical applications of leuprolide, and this
study opens the door for broader investigations into the transvaginal
delivery of peptides and proteins. Future research will determine what
other larger molecules can be absorbed transvaginally in addition to re-
ﬁning the dosing and formulations of our current delivery systems.
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